Phase <scp>III</scp>/<scp>IV</scp>, Randomized, <scp>Fifty‐Two</scp>–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus

Abstract

The primary end point of this study was not achieved, but improvement with belimumab versus placebo was observed, suggesting that belimumab remains a suitable treatment option for SLE management in patients of Black African ancestry.